Clinical trials: Newly Diagnosed Triple-negative Breast Cancer, open to volunteers
Newly Diagnosed Triple-negative Breast Cancer
A Multicenter, Randomized, Controlled Phase III Clinical Trial on Adjuvant Intensified Therapy for Patients With Residual Disease After Neoadjuvant Treatment for Triple-negative Breast Cancer
This study is a multicenter, randomized controlled phase III clinical trial. The aim of this study is to observe the efficacy and safety of PD-1 inhibitors combined with capecitabine, PD-1 inhibitors alone, or capecitabine alone…
- Trial name
- CREATE (NCT07869628)
- Testing
- Capecitabine and PD-1 inhibitor, PD-1 inhibitor, Capecitabine
- Volunteers
- 852 people
- Sponsor
- Shandong Cancer Hospital and Institute